Trials / Recruiting
RecruitingNCT07050641
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39-1 in Adult Patients With Advanced Malignant Solid Tumours
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCTB39-1 | SCTB39-1, IV |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
- First posted
- 2025-07-03
- Last updated
- 2025-07-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07050641. Inclusion in this directory is not an endorsement.